. 2021 Nov 20;15(3):732–740. doi: 10.1111/cts.13194

TABLE 2.

Pharmacokinetic parameters of remdesivir and GS‐441524 after intravenous infusion of 100 mg remdesivir at steady state

	Patients with normal renal function (N = 2)		Patients with impaired renal function (N = 2)		Patients with impaired renal function undergoing CRRT (N = 2)		Patients with impaired renal function undergoing IHD (N = 3)
Patient	A	B	C	D	E	F	G	H	I
Remdesivir
T_max,ss, h	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5	0.5
C_max,ss, μg/L	826.98	310.72	4773.30	4554.95	3713.80	11774.10	1087.30	276.04	3886.80
AUC_tau,ss, μg·h/L	4134.89	1553.60	28639.80	27329.70	22287.17	70650.09	2773.39	1032.16	4283.73
t _1/2, h	0.91	1.08	1.07	1.09	1.23	1.00	0.92	0.86	0.57
CL_ss, L/h	24.18	64.37	3.49	3.66	4.49	1.42	36.06	96.88	23.34
V _ss,obs, L	31.92	100.46	5.41	5.74	7.99	2.05	47.93	119.87	19.31
GS‐441524
T_max,ss, h	0.5	0.5	12	0.5	0.5	0.5	2.5	‐ ^a	0.5
C_max,ss, μg/L	102.44	157.07	355.74	563.30	436.32	421.32	1653.45	1280.05	706.80
AUC_tau,ss, μg·h/L	1582.35	1905.21	7728.20	11059.67	9203.09	8213.83	25615.76	26950.08	9785.21
t _1/2, h	25.47	13.27	43.74	26.20	48.57	37.80	70.44	– ^b	82.52
MR	0.38	1.23	0.27	0.40	0.41	0.12	9.24	26.11	2.28

Values are presented as the mean ± SD.

Abbreviations: AUC_tau,ss, area under the plasma concentration–time curve within a dosing interval at steady state; CL_ss, clearance at steady state; C_max,ss, maximum plasma concentration at steady state; CRRT, continuous renal replacement therapy; IHD, intermittent hemodialysis; MR, metabolite ratio; t _1/2, elimination half‐life; T_max,ss, time to maximum plasma concentration at steady state; V _ss,obs, observed volume of distribution at steady state.

^{^a}

This value was not presented because the T_max,ss at 0 h was not clinically accordant.

^{^b}

This value was not presented because it was difficult to definite terminal phase.